Search
Simcere Pharmaceutical Halts Alzheimer's Drug R&D
2 week ago /
Read about 0 minute
Author：小编
Simcere Pharmaceutical has decided to terminate its research and development efforts for Alzheimer's disease drugs. Prior to this decision, the company had collaborated with Vivoryon, investing over $500 million to secure the rights for the development and commercialization of related medications in Greater China. In 2022, Simcere received approval to conduct domestic clinical trials for these drugs. However, the total investment figure dedicated by Simcere Pharmaceutical towards the R&D of this drug remains undisclosed.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
